论文部分内容阅读
作者对３８例充血性心力衰竭（ＣＨＦ）患者采用苯那普利治疗４周，观察其治疗前后血浆肾素活性（ＰＲＡ）、血管紧张素Ⅱ（ＡｎｇⅡ）、醛固酮（ＡＬＤ）、去甲肾上腺素（ＮＥ）、肾上腺素（Ｅ）、血栓素Ｂ２（ＴＸＢ２）及６－酮－前列腺素Ｆ１２（６－ｋｅｔｏ－ＰＧＦ１α）水平的变化情况，发现治疗后患者ＰＲＡ，ＡｎｇⅡ，ＡＬＤ，ＮＥ，Ｅ，ＴＸＢ２水平均显著下降，而６－ｋｅ－ｔｏ－ＰＧＦ１α水平明显升高，并且服药后心功能改善总有效率达８４．２％。结果提示苯那普利不仅能抑制ＣＨＦ患者肾素血管紧张素系统活性，而且还能抑制交感神经系统活性、调节前列腺素代谢，改善患者的病情。
In the study, 38 patients with congestive heart failure (CHF) were treated with benazepril for 4 weeks. The changes of plasma renin activity (PRA), angiotensin Ⅱ (AngⅡ), aldosterone (ALD), norepinephrine (NE), epinephrine (E), TXB2 and 6-keto-prostaglandin F12 (6-keto-PGF1α) TXB2 levels were significantly decreased, while the 6-ke-to-PGF1α levels were significantly increased, and the improvement of cardiac function after taking the total effective rate was 84.2%. The results suggest that benazapril not only inhibits renin angiotensin system activity in patients with CHF, but also inhibit the activity of sympathetic nervous system, regulate prostaglandin metabolism and improve the patient’s condition.